Please enable Javascript
Prostate Cancer Diagnostics
Advertisement
18F-DCFPyL (PSMA) PET/CT Plus Multiparametric MRI Improves Prostate Cancer Detection
Emily Menendez
Prostate Cancer Diagnostics
|
June 25, 2025
Preliminary trial data suggests that 18F-DCFPyL PSMA PET/CT combined with mpMRI may improve csPCA detection over MRI alone.
Read More
PSMA PET-CT in Biochemical Recurrence of Prostate Cancer
Jessica Ganga
Prostate Cancer Diagnostics
|
June 25, 2025
Researchers investigated the use of PSMA PET-CT to determine treatment options for patients with biochemical failure in PC.
Read More
18F-Fluciclovine PET Detects Disease in Patients With Biochemically Recurrent Prostate Cancer
Emily Menendez
Prostate Cancer Diagnostics
|
June 25, 2025
18F-fluciclovine PET detected disease in more than half of the study’s patients with BCR and negative PSMA PET results.
Read More
Active Surveillance, MRI Can Aid in the Avoidance of Repeat Biopsies for Patients With Prostate Cancer
Emily Menendez
Prostate Cancer Diagnostics
|
May 15, 2025
The use of MRI-based monitoring can aid in the avoidance of repeat biopsies, and reduce the chances of undergoing surgery.
Read More
ctDNA in GU Oncology: History, Current Studies, and Benefits
John Sfakianos, MD
Urothelial Carcinoma Diagnostics
|
May 5, 2025
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.
View More
Maximizing Benefits and Minimizing Harm: Reviewing AUA Guidelines on Prostate Cancer Early Detection
Simpa Salami, MD, MPH
Prostate Cancer Diagnostics
|
May 5, 2025
Dr. Salami explains how updated guideline approaches shared decision-making in higher-risk groups.
View More
How PSMA PET Boosts Advancements in Oligometastatic Disease
Julian Hong, MD
Prostate Cancer Diagnostics
|
April 11, 2025
Dr. Hong reviews relevant key findings from clinical trials for oligometastatic disease.
View More
Oligometastatic Disease and Metastasis-Directed Therapy in Prostate Cancer
Julian Hong, MD
Prostate Cancer Diagnostics
|
April 11, 2025
Dr. Hong reviews the criteria used to determine which patients may benefit from MDT.
View More
Role of PSMA PET in Surgical Planning, Post-Operative Management
Carissa Chu, MD
Prostate Cancer Diagnostics
|
June 25, 2025
Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision.
View More
Using PSMA PET or SPECT to Evaluate Response to Treatment
Thomas Hope, MD
Prostate Cancer Diagnostics
|
March 31, 2025
Dr. Hope evaluates PSMA PET vs SPECT imaging for tracking therapy response in prostate cancer.
View More
PSMA-PET in Risk Stratification: OS in Patients With Prostate Cancer
Wolfgang Fendler, MD
Prostate Cancer Diagnostics
|
March 31, 2025
Dr. Fendler reviews a multi-center study that used prognostic nomograms to risk-stratify patients based on OS.
View More
PSMA and Beyond 2025: Reviewing the Agenda
Jérémie Calais, MD, PhD
RLT
|
March 26, 2025
Dr. Calais provides an overview of this year's PSMA and Beyond conference agenda.
View More
Co-PSMA Trial: Head-to-Head Comparison of 64Cu-SAR-bis-PSMA vs 68Ga-PSMA-11
Louise Emmett, MD
Prostate Cancer Diagnostics
|
March 24, 2025
Dr. Emmett discusses the Co-PSMA trial, comparing ⁶⁴Cu-SAR-bisPSMA and ⁶⁸Ga-PSMA-11 for detecting prostate cancer ...
View More
Patient Perceptions of Germline Genetic Testing Benefits for Prostate Cancer
Emily Menendez
Prostate Cancer Diagnostics
|
March 13, 2025
Germline genetic testing is underused for patients with prostate cancer, despite many being eligible for the procedure.
Read More
ASCO Releases New Recommendations on Germline and Somatic Testing for Metastatic PCa
Emily Menendez
Prostate Cancer Diagnostics
|
January 28, 2025
Patients with metastatic PCa are recommended to undergo both germline and somatic DNA sequencing using panel-based assays.
Read More
Precision Medicine in Prostate Cancer: A Multidisciplinary Discussion
Jacob Ark, MD
CRPC
|
February 3, 2025
Expert panel discusses diagnostic criteria, precision medicine, and PSMA imaging in managing metastatic prostate cancer.
View More
Clarity Pharmaceuticals Receives FDA Fast Track Designation for Cu-64 SAR-bisPSMA Prostate Cancer Imaging Agent
Brandon Twyford
Prostate Cancer Diagnostics
|
January 24, 2025
The FDA's Fast Track Designation enables expedited development of 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging.
Read More
PSMA PET Utility for Determining Optimal Candidates for Focal Therapy
Rafael Sanchez-Salas, MD
Localized
|
January 21, 2025
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
View More
BCR Treatment With Focal Therapy: PSMA PET and Salvage Prostatectomy
Jihad Kaouk, MD
Localized
|
January 21, 2025
Dr. Kaouk presented on the benefits of surgery for managing biochemically recurrent prostate cancer post-radiation.
View More
Long-Term Complications of Prostate Cancer Treatment: PSA Testing
Ian Thompson, Jr., MD
Localized
|
January 21, 2025
Dr. Thompson, Jr. highlights his recently published large dataset of long-term complications of prostate cancer treatment.
View More
Load More
Advertisement
Advertisement